The aim of the current study is an analysis of @entity5 parameters, clinical and pathological responses, medical management, and survival on 710 operable @entity0 @entity1 who received neoadjuvant chemotherapy from 1982 to 2004 and were grouped into four successive periods according to diagnosis date: (1) 1982-1989; (2) 1990-1994; (3) 1995-1999; and (4) 2000-2004. @entity1 were treated by different neoadjuvant chemotherapies combinations: AVCF/M, TNCF, NEM, NET, TAXOTERE, FEC 50, 75, 100, FAC 50, and TAXOTERE-TNCF, mainly in successive prospective phase II trials. They received a median number of six cycles (range, 1-9). After primary chemotherapy, @entity1 underwent a surgery and a radiotherapy. In case of significant @entity66 , some @entity1 received additional courses of chemotherapy. In addition, menopausal @entity1 with hormonal receptor-positive @entity5 received @entity440 for 5 yr. Clinical factors had some remarkable variations with time. The median age of the @entity1 was 49.5 yr (range, 26-81). The size of the @entity5 was significantly greater from 1995; conversely, clinical lymph-node involvement was lower in period 4 than in the first period. The percentage of @entity513 increased about 20% from 1982-1989 to 2000-2004. The number of positive hormonal receptors increased from 38.3% in period 1 to 74% in period 4. The clinical response rate improved recently from before 1990. The pathological response rate was greater in periods 2 and 3 than in periods 1 and 4. An adjuvant hormonotherapy became progressively more frequently given (44.7 for period 1 and 73.3% for period 4). Finally, no significant difference was found when we compared overall and disease-free survival through the four periods. It appears that the progressive increase of @entity5 burden was compensated by more effective treatments.

@entity5 parameters, clinical and pathological responses, medical management, and survival through time on 710 operable XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity513 :: ('MESH:D044584', 'Disease') :: ['invasive ductal carcinoma and of SBR III tumors']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancers']
